$TNYA
Tenaya Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023020609 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.627M $8.118M $6.999M
YoY Change 11.42% 15.99% 99.12%
% of Gross Profit
Research & Development $26.48M $25.61M $24.16M
YoY Change 26.83% 6.0% 151.88%
% of Gross Profit
Depreciation & Amortization $2.195M $2.130M $966.0K
YoY Change 69.24% 120.5% 40.2%
% of Gross Profit
Operating Expenses $35.10M $33.72M $31.15M
YoY Change 22.66% 8.25% 137.73%
Operating Profit -$35.10M -$33.72M -$31.15M
YoY Change 22.66% 8.25% 137.73%
Interest Expense $1.837M $1.973M $99.00K
YoY Change 727.48% 1892.93% 1000.0%
% of Operating Profit
Other Income/Expense, Net $1.835M $1.986M $98.00K
YoY Change 726.58% 1926.53% 1300.0%
Pretax Income -$33.27M -$31.74M -$31.06M
YoY Change 17.16% 2.19% 137.1%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$33.27M -$31.70M -$31.06M
YoY Change 17.16% 2.07% 137.1%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.43 -$0.75
Diluted Earnings Per Share -$0.45 -$0.43 -$752.5K
COMMON SHARES
Basic Shares Outstanding 66.87M 66.87M 41.29M
Diluted Shares Outstanding 73.40M 73.10M 41.27M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $132.5M $147.8M $210.5M
YoY Change -26.76% -29.76% 63.86%
Cash & Equivalents $75.57M $72.54M $25.97M
Short-Term Investments $56.94M $75.27M $184.5M
Other Short-Term Assets $6.401M $6.815M $3.328M
YoY Change 34.0% 104.78% 153.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $138.9M $154.6M $213.8M
YoY Change -25.2% -27.67% 64.76%
LONG-TERM ASSETS
Property, Plant & Equipment $47.04M $49.35M $49.38M
YoY Change -11.27% -0.06% 92.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.14M $25.82M
YoY Change
Other Assets $5.540M $4.630M $6.579M
YoY Change 49.33% -29.62% 52.12%
Total Long-Term Assets $81.85M $90.71M $67.72M
YoY Change 16.53% 33.96% 125.66%
TOTAL ASSETS
Total Short-Term Assets $138.9M $154.6M $213.8M
Total Long-Term Assets $81.85M $90.71M $67.72M
Total Assets $220.8M $245.3M $281.5M
YoY Change -13.74% -12.84% 76.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.484M $7.430M $8.888M
YoY Change 58.67% -16.4% 324.86%
Accrued Expenses $8.986M $8.145M $8.132M
YoY Change -5.39% 0.16% 121.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.92M $19.31M $19.10M
YoY Change 11.61% 1.1% 223.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $240.0K $234.0K $212.0K
YoY Change 10.6% 10.38% -97.0%
Total Long-Term Liabilities $240.0K $234.0K $212.0K
YoY Change 10.6% 10.38% -97.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.92M $19.31M $19.10M
Total Long-Term Liabilities $240.0K $234.0K $212.0K
Total Liabilities $30.81M $29.93M $32.40M
YoY Change -3.89% -7.63% 149.9%
SHAREHOLDERS EQUITY
Retained Earnings -$344.2M -$310.9M -$186.6M
YoY Change 60.09% 66.61%
Common Stock $7.000K $7.000K $4.000K
YoY Change 75.0% 75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $189.9M $215.4M $249.1M
YoY Change
Total Liabilities & Shareholders Equity $220.8M $245.3M $281.5M
YoY Change -13.74% -12.84% 76.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$33.27M -$31.70M -$31.06M
YoY Change 17.16% 2.07% 137.1%
Depreciation, Depletion And Amortization $2.195M $2.130M $966.0K
YoY Change 69.24% 120.5% 40.2%
Cash From Operating Activities -$26.22M -$30.29M -$28.76M
YoY Change 3.11% 5.33% 82.13%
INVESTING ACTIVITIES
Capital Expenditures $208.0K $629.0K $8.595M
YoY Change -102.9% -92.68% 98.82%
Acquisitions
YoY Change
Other Investing Activities $25.29M $12.00K $25.03M
YoY Change -32.35% -99.95%
Cash From Investing Activities $25.09M $8.061M $16.43M
YoY Change -16.96% -50.95% -480.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.179M -501.0K 15.00K
YoY Change 1507.31% -3440.0% -99.93%
NET CHANGE
Cash From Operating Activities -26.22M -30.29M -28.76M
Cash From Investing Activities 25.09M 8.061M 16.43M
Cash From Financing Activities 4.179M -501.0K 15.00K
Net Change In Cash 3.044M -22.73M -12.31M
YoY Change -39.6% 84.69% 12587.63%
FREE CASH FLOW
Cash From Operating Activities -$26.22M -$30.29M -$28.76M
Capital Expenditures $208.0K $629.0K $8.595M
Free Cash Flow -$26.43M -$30.92M -$37.35M
YoY Change 44.78% -17.22% 85.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001858848
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40656
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TENAYA THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3789973
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
171 Oyster Point Boulevard
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
825-6990
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TNYA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66869868
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72542000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95272000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
75271000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
91255000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6815000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7227000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
154628000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
193754000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49352000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51032000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10909000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11663000
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
25822000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
17703000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4630000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4793000
CY2023Q1 us-gaap Assets
Assets
245341000
CY2022Q4 us-gaap Assets
Assets
278945000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7430000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9578000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8145000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10664000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3730000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4006000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19305000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24248000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10390000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11093000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
234000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
228000
CY2023Q1 us-gaap Liabilities
Liabilities
29929000
CY2022Q4 us-gaap Liabilities
Liabilities
35569000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
526460000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
522945000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-120000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-378000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310935000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279198000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
215412000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
243376000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
245341000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278945000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25605000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24155000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8118000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6999000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
33723000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
31154000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33723000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-31154000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1973000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
99000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1986000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
98000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31737000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31056000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31737000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31056000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
258000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-490000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31479000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31546000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73097889
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73097889
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41267990
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41267990
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
243376000
CY2023Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3514000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
258000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31737000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
215412000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2022Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
6000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2094000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-490000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31056000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
249097000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-31737000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-31056000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2130000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
966000
CY2023Q1 tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-567000
CY2022Q1 tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
143000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3514000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2094000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
754000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
332000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-52000
CY2023Q1 tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-366000
CY2022Q1 tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-732000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-163000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-25000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1324000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1779000
CY2023Q1 tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-2662000
CY2022Q1 tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
318000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-979000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-533000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30290000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28756000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
629000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8595000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
25798000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
43171000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34500000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68200000
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
12000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8061000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16434000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
501000
CY2022Q1 tnya Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
15000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-501000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22730000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12307000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95671000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38676000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72941000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26369000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72542000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25970000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
399000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
399000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72941000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26369000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
370000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5282000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310900000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31700000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31100000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
173600000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accrued liabilities, income tax valuation allowance and stock-based compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Management bases its estimates on historical experience, the current economic environment, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></p>
CY2023Q1 tnya Impairment Charges On Marketable Securities Related To Other Than Temporary
ImpairmentChargesOnMarketableSecuritiesRelatedToOtherThanTemporary
0
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
75300000
CY2023Q1 tnya Available For Sale Securities Debt Maturities One And Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesOneAndTwoYearsFairValue
25800000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67158000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
66708000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17806000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15676000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49352000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51032000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000.0
CY2023Q1 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
3255000
CY2022Q4 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
6299000
CY2023Q1 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2910000
CY2022Q4 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3214000
CY2023Q1 tnya Accrued Employee Stock Purchase Plan Deduction Liability
AccruedEmployeeStockPurchasePlanDeductionLiability
544000
CY2022Q4 tnya Accrued Employee Stock Purchase Plan Deduction Liability
AccruedEmployeeStockPurchasePlanDeductionLiability
124000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
476000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
482000
CY2023Q1 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
283000
CY2022Q4 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
139000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
677000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
406000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8145000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10664000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1090000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
702000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
273000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
238000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
226000
CY2023Q1 us-gaap Lease Cost
LeaseCost
1368000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1166000
CY2023Q1 tnya Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
1593000
CY2022Q1 tnya Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
1366000
CY2023Q1 tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
1315000
CY2022Q1 tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
902000
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3908000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3910000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2445000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1386000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1428000
CY2023Q1 tnya Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5477000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18554000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4434000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
14120000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.95
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.040
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.021
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3514000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2094000
CY2023Q1 tnya Pre Funded Warrants Exercised
PreFundedWarrantsExercised
0
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18666093
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9134552
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4882411

Files In Submission

Name View Source Status
tnya-20230331_pre.xml Edgar Link unprocessable
0000950170-23-020609-index-headers.html Edgar Link pending
0000950170-23-020609-index.html Edgar Link pending
0000950170-23-020609.txt Edgar Link pending
0000950170-23-020609-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnya-20230331.htm Edgar Link pending
tnya-20230331.xsd Edgar Link pending
tnya-ex10_1.htm Edgar Link pending
tnya-ex31_1.htm Edgar Link pending
tnya-ex31_2.htm Edgar Link pending
tnya-ex32_1.htm Edgar Link pending
tnya-20230331_def.xml Edgar Link unprocessable
tnya-20230331_cal.xml Edgar Link unprocessable
tnya-20230331_lab.xml Edgar Link unprocessable
tnya-20230331_htm.xml Edgar Link completed